Last Updated : June 17, 2019
Details
Generic Name:
iIbritumomab tiuxetan
Project Status:
Not filed
Therapeutic Area:
Non-Hodgkin’s Lymphoma (NHL)
Manufacturer:
Servier Canada Inc.
Brand Name:
Zevalin
Project Line:
Reimbursement Review
Project Number:
NS0003-000
Submission Type:
Non-submission
Fee Schedule:
N/A
Tumour Type:
Lymphoma
Indications:
Non-Hodgkin’s Lymphoma (NHL)
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : June 17, 2019